Cardiovascular Toxicity of CDK4/6 Inhibitors in Breast Cancer: JACC: CardioOncology Primer.

Kisqali (ribociclib) - Novartis

Ibrance (palbociclib) - Pfizer

Verzenio (abemaciclib) - Eli Lilly

Cardiovascular Toxicity of CDK4/6 Inhibitors in Breast Cancer: JACC: CardioOncology Primer. (PubMed, JACC CardioOncol) - Oct 7, 2026 - No abstract available
Journal • Review • Breast Cancer • Cardiovascular • Oncology • Solid Tumor

http://www.ncbi.nlm.nih.gov/pubmed/42836806

Douglas E Drachman; Erica L Mayer; Michelle Li

Oct 7, 2026